{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T09:16:20Z","timestamp":1785402980697,"version":"3.56.0"},"reference-count":10,"publisher":"American Association for Cancer Research (AACR)","issue":"4","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,4,1]]},"abstract":"<jats:title>Summary:<\/jats:title>\n                  <jats:p>The study by Fece de la Cruz, Varkaris, and colleagues uncovered a critical mechanism underlying resistance to the p53-Y220C reactivator rezatapopt in the PYNNACLE clinical trial. Specifically, rezatapopt treatment was shown to select for secondary mutations in the TP53 gene on the Y220C-mutant background, thereby abrogating its therapeutic efficacy.<\/jats:p>\n                  <jats:p>See related article by Fece de la Cruz et al., p. 677<\/jats:p>","DOI":"10.1158\/2159-8290.cd-26-0153","type":"journal-article","created":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T07:15:52Z","timestamp":1775027752000},"page":"620-622","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The Moving Target:\n                    <i>Cis<\/i>\n                    -Mutation\u2013Driven Resistance to p53-Y220C Reactivator"],"prefix":"10.1158","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3520-1887","authenticated-orcid":false,"given":"Yanqing","family":"Liu","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00hj8s172","id-type":"ROR","asserted-by":"publisher"}],"name":"Columbia University 1 Institute for Cancer Genetics, Herbert Irving Comprehensive Cancer Center, , New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1480-2368","authenticated-orcid":false,"given":"Wei","family":"Gu","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00hj8s172","id-type":"ROR","asserted-by":"publisher"}],"name":"Columbia University 1 Institute for Cancer Genetics, Herbert Irving Comprehensive Cancer Center, , New York, New York."},{"id":[{"id":"https:\/\/ror.org\/00hj8s172","id-type":"ROR","asserted-by":"publisher"}],"name":"Columbia University 2 Department of Pathology and Cell Biology, Vagelos College of Physicians & Surgeons, , New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2026,4,1]]},"reference":[{"key":"2026040103154761400_bib1","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1016\/j.ccell.2024.04.009","article-title":"Understanding the complexity of p53 in a new era of tumor suppression","volume":"42","author":"Liu","year":"2024","journal-title":"Cancer Cell"},{"key":"2026040103154761400_bib2","doi-asserted-by":"crossref","first-page":"a026179","DOI":"10.1101\/cshperspect.a026179","article-title":"Somatic TP53 mutations in the era of genome sequencing","volume":"6","author":"Hainaut","year":"2016","journal-title":"Cold Spring Harb Perspect Med"},{"key":"2026040103154761400_bib3","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/s41573-022-00571-8","article-title":"Drugging p53 in cancer: one protein, many targets","volume":"22","author":"Hassin","year":"2023","journal-title":"Nat Rev Drug Discov"},{"key":"2026040103154761400_bib4","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1021\/acschembio.9b00748","article-title":"Targeting cavity-creating p53 cancer mutations with small-molecule stabilizers: the Y220X paradigm","volume":"15","author":"Bauer","year":"2020","journal-title":"ACS Chem Biol"},{"key":"2026040103154761400_bib5","doi-asserted-by":"crossref","first-page":"4861","DOI":"10.1007\/s11030-024-11045-x","article-title":"Small molecules that targeting p53 Y220C protein: mechanisms, structures, and clinical advances in anti-tumor therapy","volume":"29","author":"Xu","year":"2025","journal-title":"Mol Divers"},{"key":"2026040103154761400_bib6","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.1038\/sj.onc.1210291","article-title":"Structure-function-rescue: the diverse nature of common p53 cancer mutants","volume":"26","author":"Joerger","year":"2007","journal-title":"Oncogene"},{"key":"2026040103154761400_bib7","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1158\/2159-8290.CD-22-0381","article-title":"A small molecule reacts with the p53 somatic mutant Y220C to rescue wild-type thermal stability","volume":"13","author":"Guiley","year":"2023","journal-title":"Cancer Discov"},{"key":"2026040103154761400_bib8","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1158\/2159-8290.CD-24-1421","article-title":"Restoration of the tumor suppressor function of Y220C-mutant p53 by rezatapopt, a small-molecule reactivator","volume":"15","author":"Puzio-Kuter","year":"2025","journal-title":"Cancer Discov"},{"key":"2026040103154761400_bib9","doi-asserted-by":"crossref","first-page":"3159","DOI":"10.1080\/14796694.2025.2557176","article-title":"PYNNACLE phase II clinical trial protocol: rezatapopt (PC14586) monotherapy in advanced or metastatic solid tumors with a TP53 Y220C mutation","volume":"21","author":"Schram","year":"2025","journal-title":"Future Oncol"},{"key":"2026040103154761400_bib10","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1158\/2159-8290.CD-25-1761","article-title":"Acquired on-target alterations drive clinical resistance to p53-Y220C reactivators","volume":"16","author":"Fece de la Cruz","year":"2026","journal-title":"Cancer Discov"}],"container-title":["Cancer Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article-pdf\/16\/4\/620\/3749541\/cd-26-0153.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article-pdf\/16\/4\/620\/3749541\/cd-26-0153.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T07:15:54Z","timestamp":1775027754000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article\/16\/4\/620\/775554\/The-Moving-Target-Cis-Mutation-Driven-Resistance"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,1]]},"references-count":10,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,4,1]]},"published-print":{"date-parts":[[2026,4,1]]}},"URL":"https:\/\/doi.org\/10.1158\/2159-8290.cd-26-0153","relation":{},"ISSN":["2159-8274","2159-8290"],"issn-type":[{"value":"2159-8274","type":"print"},{"value":"2159-8290","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,1]]}}}